Stroke
Conditions
Brief summary
The purpose of the clinical trial is to find a treatment for stroke patients with cognitive impairment, and the main questions it aims to answer are: * \[Search for effective treatments of cognitive impairment after stroke\] * \[explore the relationship between BDNF level and cognitive function\] Participants will receive conventional treatment, tDCS treatment, .And then compare cognitive function and BDNF level
Detailed description
1. To study the therapeutic effect of transcranial direct current stimulation (tDCS) on post-stroke cognitive impairment (PSCI) by evaluating cognitive function and detecting plasma brain-derived neurotrophic factor (BDNF). 2. To explore the correlation between plasma BDNF level and cognitive function in patients with PSCI.
Interventions
OTHERRoutine treatment
Both groups were given routine treatment
OTHERTranscranial Direct Current Stimulation
The common group routine training used sham TDCS stimulation, and the experimental group used real TDCS stimulation
Sponsors
The Second Affiliated Hospital of Dalian Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* (1)Stroke patients with CT or MRI imaging evidence, among which ischemic stroke met the diagnostic criteria of Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018, and cerebral hemorrhage diseases met the diagnostic criteria of Chinese Guidelines for the Diagnosis and Treatment of Cerebral hemorrhage 2019; (2) There are symptoms related to cognitive dysfunction; Cognitive dysfunction was assessed by rehabilitation physicians. According to the MoCA evaluation standard,MoCA score ≤26 points; according to the MMSE evaluation standard, illiteracy score ≤17 points; primary school education level ≤20 points; secondary school education (including secondary school) level ≤22 points; college education (including junior college) level ≤23 points; (3)Age range 40-80 years old; (4) no obvious aphasia, speech expression and attention can cooperate with the completion of evaluation and treatment; (5)The patient or the patient's family members read and agree to sign the informed consent.
Exclusion criteria
* (1) Patients with severe diseases, such as malignant arrhythmia, acute myocardial infarction and acute heart failure, who cannot tolerate rehabilitation treatment; (2) Patients with untreated intracranial aneurysms, severe epilepsy, and intracranial metals who cannot receive tDCS treatment; (3) Non-PSCI patients with cognitive impairment, including patients with cognitive impairment left over from previous stroke and other organ disorders.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| BDNF | 2 weeks | Plasma BDNF was determined by elisa |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cognitive function level | 2 weeks | Score of Mini-Mental State Examination(MMSE) and Montreal Cognitive Assessment(MoCA) |
| Executive function level | 2 weeks | core of The Frontal Assessment Battery（FAB） |
| Memory function level | 2 weeks | Score of Rivermead Behavioral Memory Test（RBMT） |
Countries
China
Contacts
Primary ContactYang Tu
Backup ContactRen
Outcome results
None listed